TW234691B - - Google Patents

Info

Publication number
TW234691B
TW234691B TW082101725A TW82101725A TW234691B TW 234691 B TW234691 B TW 234691B TW 082101725 A TW082101725 A TW 082101725A TW 82101725 A TW82101725 A TW 82101725A TW 234691 B TW234691 B TW 234691B
Authority
TW
Taiwan
Prior art keywords
prostaglandin
wounds
derivatives
active ingredient
hemorrhoids
Prior art date
Application number
TW082101725A
Other languages
English (en)
Chinese (zh)
Original Assignee
Kaken Pharma Co Ltd
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd, Toray Industries filed Critical Kaken Pharma Co Ltd
Application granted granted Critical
Publication of TW234691B publication Critical patent/TW234691B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
TW082101725A 1992-02-07 1993-03-09 TW234691B (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2280892 1992-02-07
JP18986792 1992-06-24

Publications (1)

Publication Number Publication Date
TW234691B true TW234691B (ko) 1994-11-21

Family

ID=26360087

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082101725A TW234691B (ko) 1992-02-07 1993-03-09

Country Status (8)

Country Link
US (3) US5403867A (ko)
EP (1) EP0583482B1 (ko)
JP (1) JP3209427B2 (ko)
AT (1) ATE188119T1 (ko)
CA (1) CA2107669C (ko)
DE (1) DE69327432T2 (ko)
TW (1) TW234691B (ko)
WO (1) WO1993015739A1 (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
US5403867A (en) * 1992-02-07 1995-04-04 Kaken Pharmaceutical Co., Ltd. Preparation for treating wounds or hemorrhoids
CA2174737C (en) * 1993-10-29 2008-04-22 Douglas V. Faller Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
IT1269634B (it) * 1994-05-06 1997-04-08 Indena Spa Medicamento topico ad attivita' cicatrizzante
US5965611A (en) * 1994-06-02 1999-10-12 Teigin Limited Pharmaceutical composition for treating peripheral circulation disorders
DE69527507T2 (de) * 1994-11-17 2002-11-07 Toray Industries Transdermal absorbierbare zubereitung
AU4732096A (en) * 1995-02-27 1996-09-18 Toray Industries, Inc. Remedy for pulmonary heart
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5869059A (en) * 1996-01-16 1999-02-09 Mon's Tea Partnership Herbal composition for hemorrhoid treatment
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
US6365198B1 (en) * 2001-01-28 2002-04-02 Gulf Pharmaceutical Industries Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids
US20040266880A1 (en) * 2002-02-22 2004-12-30 Fumie Sato Antipruritics
US7737182B2 (en) * 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
CA2465103C (en) * 2002-08-09 2011-04-26 Taisho Pharmaceutical Co., Ltd. Use of a prostaglandin derivative as an anti-pruritic agent
EP1608378A1 (en) 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
EP1642584A1 (en) * 2003-06-25 2006-04-05 Cardiovascular Institute, Ltd External preparation for improving coital function
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
EP2509418A4 (en) 2009-12-08 2013-03-20 Hemaquest Pharmaceuticals Inc METHODS AND REGIMES AT LOW DOSE FOR TREATING RED GLOBULAR DISORDERS
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
US8940794B2 (en) 2011-04-07 2015-01-27 Nexmed Holdings, Inc. Methods and compositions for treating Raynaud's disease
US9345678B2 (en) 2013-03-13 2016-05-24 Allergan, Inc. Prostanoid receptor agonist compounds and methods of use for same
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK142235B (da) * 1974-12-20 1980-09-29 Yamanouchi Pharma Co Ltd Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater.
US4025645A (en) * 1976-01-27 1977-05-24 Jelenko Iii Carl Non-steroid topical agent for alleviating inflammation in mammals
GB1595056A (en) * 1976-10-12 1981-08-05 Wellcome Found Pharmaceutical combination
JPS5391110A (en) * 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
DE3162659D1 (en) * 1980-07-22 1984-04-19 Ono Pharmaceutical Co 9,11-methano-13-aza-11a-carbathrombanoic acid analogues and pharmaceutical use thereof
DE3631169A1 (de) * 1986-09-11 1988-03-24 Schering Ag Prostacyclinderivate enthaltende mittel fuer die topische anwendung
EP0365678B1 (en) * 1987-10-16 1994-01-05 Toray Industries, Inc. 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF
JPH0311017A (ja) * 1989-06-06 1991-01-18 Green Cross Corp:The プロスタグランジンｅ↓１含有薬剤組成物
ATE141794T1 (de) * 1991-03-14 1996-09-15 R Tech Ueno Ltd Stimulierung von wundheilung mit 15-keto- prostaglandinverbindungen
US5403867A (en) * 1992-02-07 1995-04-04 Kaken Pharmaceutical Co., Ltd. Preparation for treating wounds or hemorrhoids
AU669783B2 (en) * 1993-02-03 1996-06-20 Teijin Limited Dermatologic preparation composition containing prostacyclinas active ingredient

Also Published As

Publication number Publication date
EP0583482A4 (en) 1995-05-03
US5679707A (en) 1997-10-21
DE69327432T2 (de) 2000-05-18
EP0583482B1 (en) 1999-12-29
EP0583482A1 (en) 1994-02-23
ATE188119T1 (de) 2000-01-15
JP3209427B2 (ja) 2001-09-17
US5403867A (en) 1995-04-04
CA2107669A1 (en) 1993-08-08
DE69327432D1 (de) 2000-02-03
WO1993015739A1 (en) 1993-08-19
US5852050A (en) 1998-12-22
CA2107669C (en) 2004-06-01

Similar Documents

Publication Publication Date Title
TW234691B (ko)
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
AU549481B2 (en) Hair growing agent
AU1399492A (en) Remedies for bone diseases
EP0379806A3 (en) Pyrimidines and their pharmaceutical acceptable salts, and their use as medicines
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
AU6542986A (en) Pyridyl-methylthio substituted benzimidazoles
GB8804164D0 (en) Bandage for administering physiologically active compound
IE882583L (en) Treatment of wounds
AU4697393A (en) Pharmaceutical and/or cosmetic preparation and the use of the preparation
GR3023825T3 (en) Benzopyran derivatives, processes for their preparation and their use and preparations containing the compounds
CA2125662A1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
AU3354895A (en) Novel medicinal use of 5ht3 antagonist
EP0620004A4 (en) MEDICAL COMPOSITION.
AU1518492A (en) Pharmaceutical compositions for transcutaneous administration
PH27446A (en) Compound with gastric acid inhibitory effect
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
EP0495106A4 (en) Osteogenesis promoter
HU9201358D0 (en) 2-amino-pirimidine-4-carboxamide derivatives, process for their production and for the production of medical preparations containing them as active agents
AU3401093A (en) Therapeutic agent for threatened abortion
ES2000681A6 (es) Un procedimiento para preparar nuevos compuestos de bencilpiperazina
EP0351876A3 (en) Composition for potentiating vaccination effect
WO1987003590A1 (en) Medicament for the treatment of diseases of the liver
GR3004113T3 (ko)
NO167801C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,2'-bi-1h-imidazolderivater.